|
US$179.00 · In stock
Delivery: <= 3 days. True-PDF full-copy in English will be manually translated and delivered via email.
YY/T 1913-2023: Determination of 2, 2-bis (4-hydroxyphenyl) propane (bisphenol A) residues in medical polycarbonate materials
Status: Valid
| Standard ID | Contents [version] | USD | STEP2 | [PDF] delivered in | Standard Title (Description) | Status | PDF |
| YY/T 1913-2023 | English | 179 |
Add to Cart
|
3 days [Need to translate]
|
Determination of 2, 2-bis (4-hydroxyphenyl) propane (bisphenol A) residues in medical polycarbonate materials
| Valid |
YY/T 1913-2023
|
PDF similar to YY/T 1913-2023
Basic data | Standard ID | YY/T 1913-2023 (YY/T1913-2023) | | Description (Translated English) | Determination of 2, 2-bis (4-hydroxyphenyl) propane (bisphenol A) residues in medical polycarbonate materials | | Sector / Industry | Medical Device & Pharmaceutical Industry Standard (Recommended) | | Classification of Chinese Standard | C31 | | Classification of International Standard | 11.040.30 | | Word Count Estimation | 9,934 | | Date of Issue | 2023-09-05 | | Date of Implementation | 2024-09-15 | | Issuing agency(ies) | State Drug Administration | | Summary | This standard specifies the method for determination of 2,2-bis(4-hydroxyphenyl)propane (bisphenol A) residue in medical polycarbonate materials. This standard is applicable to the determination of 2,2-bis(4-hydroxyphenyl)propane (bisphenol A) residue in medical polycarbonate materials. | YY/T 1913-2023: Determination of 2, 2-bis (4-hydroxyphenyl) propane (bisphenol A) residues in medical polycarbonate materials
---This is a DRAFT version for illustration, not a final translation. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.) will be manually/carefully translated upon your order.
ICS 11.040.30
CCSC31
Pharmaceutical Industry Standards of the People's Republic of China
2,2-bis(4-hydroxyphenyl) in medical polycarbonate materials
Method for determination of propane (bisphenol A) residue
Published on 2023-09-05
Implemented on 2024-09-15
Released by the State Drug Administration
Foreword
This document complies with the provisions of GB/T 1.1-2020 "Standardization Work Guidelines Part 1.Structure and Drafting Rules of Standardization Documents"
Drafting.
Please note that some content in this document may be subject to patents. The publisher of this document assumes no responsibility for identifying patents.
This document is proposed by the National Medical Products Administration.
This document is under the jurisdiction of the National Standardization Technical Committee for Biological Evaluation of Medical Devices (SAC/TC248).
This document was drafted by. Shandong Medical Device and Drug Packaging Inspection Institute, Shandong Zhongbaokang Medical Device Co., Ltd., Liaoning Province
Medical Device Inspection and Testing Institute, Lifetech Technology (Shenzhen) Co., Ltd.
The main drafters of this document. Guo Lijuan, Qu Ruilian, Yu Yang, He Fa, Li Feifei, Gong Bengang, Wang Shiqi, Ruan Chengxiang, Li Qiuying, Liu Chunyue,
Zhang Liying.
Introduction
This document provides guidance methods for the determination of 2,2-bis(4-hydroxyphenyl)propane (bisphenol A) residues in medical polycarbonate materials.
Medical polycarbonate material is a high molecular polymer containing carbonate groups in the molecular chain. According to the structure of the ester group, it is divided into aliphatic, aromatic, and fatty.
Aliphatic-aromatic and other types. Aromatic polycarbonate has better mechanical properties than other types of polycarbonate materials and is widely used in
medical field.
Bisphenol A is one of the synthetic monomers of aromatic polycarbonate materials. Bisphenol A may remain in the polycarbonate production process. Pro
When the bed is used, residual bisphenol A in polycarbonate medical devices has the risk of migrating into the patient's body. When bisphenol A is introduced into the human body, it may
Causes diseases such as diabetes, cardiovascular and cerebrovascular and reproductive systems, thus affecting the normal functions of the body. Therefore, it is necessary to monitor the double content of medical polycarbonate materials.
The residual amount of phenol A is very necessary.
2,2-bis(4-hydroxyphenyl) in medical polycarbonate materials
Method for determination of propane (bisphenol A) residue
1 Scope
This document describes a method for the determination of 2,2-bis(4-hydroxyphenyl)propane (bisphenol A) residues in medical polycarbonate materials.
This document is applicable to the determination of 2,2-bis(4-hydroxyphenyl)propane (bisphenol A) residue in medical polycarbonate materials.
2 Normative reference documents
The contents of the following documents constitute essential provisions of this document through normative references in the text. Among them, the dated quotations
For undated referenced documents, only the version corresponding to that date applies to this document; for undated referenced documents, the latest version (including all amendments) applies to
this document.
GB/T 6682 Specifications and test methods for water used in analytical laboratories
3 Terms and definitions
The following terms and definitions apply to this document.
3.1
extreme extractionexhaustiveextraction
Perform multi-step leaching until the leached substance is measured gravimetrically (or achieved by other methods) in subsequent leaching steps.
The amount is less than 10% of the amount measured in the first extraction.
[Source. ISO 10993-18.2020,3.15]
3.2
Leaching that is expected to result in the release of greater or greater amounts of chemical constituents than would be expected under clinical use conditions.
NOTE. It is important to ensure that intensive leaching does not result in chemical changes in the material or substance being leached.
[Source. ISO 10993-18.2020,3.14]
3.3
simulated extraction
Extraction using a method that simulates clinical use.
NOTE. The purpose of conducting simulated leaching is to estimate the type and amount of substances expected to be released from the medical device during clinical use. Simulated leaching aims to generate a
Leachables spectrum, which represents the worst-case leachables spectrum, i.e., all leachables are also leachables, and the levels of all individual leachables
At least equal to the level of all individual leachables.
[Source. ISO 10993-18.2020, 3.35, with modifications]
4 General requirements
4.1 The room temperature in this document, unless otherwise specified, should be 10℃~30℃.
4.2 The test water used in this document should comply with the requirements for secondary water in GB/T 6682.
Tips & Frequently Asked Questions:Question 1: How long will the true-PDF of YY/T 1913-2023_English be delivered?Answer: Upon your order, we will start to translate YY/T 1913-2023_English as soon as possible, and keep you informed of the progress. The lead time is typically 1 ~ 3 working days. The lengthier the document the longer the lead time. Question 2: Can I share the purchased PDF of YY/T 1913-2023_English with my colleagues?Answer: Yes. The purchased PDF of YY/T 1913-2023_English will be deemed to be sold to your employer/organization who actually pays for it, including your colleagues and your employer's intranet. Question 3: Does the price include tax/VAT?Answer: Yes. Our tax invoice, downloaded/delivered in 9 seconds, includes all tax/VAT and complies with 100+ countries' tax regulations (tax exempted in 100+ countries) -- See Avoidance of Double Taxation Agreements (DTAs): List of DTAs signed between Singapore and 100+ countriesQuestion 4: Do you accept my currency other than USD?Answer: Yes. If you need your currency to be printed on the invoice, please write an email to [email protected]. In 2 working-hours, we will create a special link for you to pay in any currencies. Otherwise, follow the normal steps: Add to Cart -- Checkout -- Select your currency to pay.
|